Market Signal Briefing

A BYD logo is displayed on a car at a dealership in Sant Cugat del Valles, near Barcelona, Spain, September 12, 2025. REUTERS/ Albert Gea/File Photo Purchase Licensing Rights, opens new tab

CompaniesOct 14 (Reuters) - China's No. 1 automaker BYD

(002594.SZ), opens new tab considers Spain to be its top candidate for a third car factory to serve the European market, two people briefed on the matter told Reuters, as the company seeks to grow sales on the continent.

A BYD assembly plant, joining two other planned factories in Hungary and Turkey, would be a significant boost for the carmaker that competes with Tesla, and would also bolster Spain's aim of becoming a major hub for electric vehicle production.

Sign up here.

One of the sources said Spain is favoured by BYD because of its relatively low manufacturing costs and clean energy network.

While it is known that BYD has been looking for a third plant to serve the European market, Spain's emergence as a frontrunner has been previously unreported.

ANY DECISION NEEDS SIGN-OFF IN CHINABYD country manager for Spain and Portugal Alberto De Aza told Reuters last month that Spain would be an ideal location for further expansion of BYD's European manufacturing footprint because of its industrial infrastructure and cheap electricity.

A third source cautioned that the company has not communicated any final decision and was still considering other countries besides Spain. A final decision on the plant, which should come before the end of the year, will need to be approved by Chinese regulators.

Reuters reported in March that BYD has looked at other countries including Germany, though that has been debated internally because of high labour and energy costs.

Both Spain's Industry Ministry and BYD declined to comment.

BYD AIMS TO MAKE ALL CARS FOR EUROPE LOCALLY IN THREE YEARSBYD's sales in Europe jumped 280% in the first eight months of the year from the same period in 2024 after the automaker began selling plug-in hybrids as well as fully electric cars.

Reuters reported in April that BYD had overhauled its European operations to boost sales by hiring more managers and adding dealerships.

Diplomatic and business ties between Spain and China have warmed considerably in recent years. Last year, Spain abstained on a European Union vote on tariffs on Chinese-made EVs.

China's government privately told automakers to halt investments in European countries that supported those tariffs, Reuters reported last year. Germany voted against the tariffs.

Spain, Europe's second-largest car-producing nation, has attracted major investments including from Germany's Volkswagen and China's Chery and CATL since it announced a 5 billion euro ($5.8 billion) plan in 2020 to attract EV and battery manufacturing using EU pandemic relief funds.

BYD aims to produce all EVs for sale in Europe locally within three years, which would help it avoid EU tariffs.

Its planned factory in Hungary is currently under construction, though sources told Reuters in July that BYD has pushed back its timeline for mass production at the plant until next year. Its Turkish plant is due to open in 2026.

($1 = 0.8618 euros)

By Reuters Staff; Editing by Nick Carey and Jan Harvey

Our Standards: The Thomson Reuters Trust Principles., opens new tab

Journalist

Posted: October 14, 2025

Key Takeaways
Will PancakeSwap sustain its upward momentum?
CAKE formed a bullish engulfing candle at the 200 EMA and broke its descending trendline, signaling potential continuation toward $4.5.

Are traders and investors supporting this rebound?
Yes. Spot Taker CVD stayed green, confirming buy dominance, while $1.1 million in outflows reflected strong accumulation.

After a 61.5% price crash in PancakeSwap [CAKE] during the historic crypto crash on the 10th of October, the market has shown a strong rebound, potentially opening the door to a further rally.

The bounce from the $3 support zone aligned with rising trader activity and bullish on-chain data, hinting that a wider rally could be in play.

CAKE’s price momentum returns
CAKE traded at $3.48 at press time, up 25% in 24 hours. Trading volume jumped 155% to $660 million, indicating renewed interest among retail and whale accounts.

AMBCrypto’s technical analysis revealed that this price surge pushed CAKE back above the key support level of $3.

Moreover, on the daily chart, the altcoin formed a strong bullish engulfing candlestick pattern, with the price continuing to maintain its upward momentum.

Source: TradingView

A break above the descending trendline on the 4-hour chart confirmed momentum shift to buyers.

Source: TradingView

If the momentum continues and the price holds above the key support of $3, CAKE could see a 28% surge and may reach the $4.50 level.

The Average Directional Index (ADX) stood at 28, signaling a strong trend, while the 200-day EMA ($2.56) acted as firm support.

Expert predictions fuel optimism
Given the market sentiment, several experts surfaced with bold predictions on CAKE.

Crypto commentator CoinQTS projected that CAKE had just begun its journey with huge potential and hinted that it may reach the $20 level in the coming days.

Meanwhile, another expert predicted that CAKE could hit $5 in the coming days.

The Wolf Insight highlighted five catalysts for CAKE’s rally: the Cake.Pad launch for IFO access, 28.8 million CAKE burned in September, $772 billion Q3 volume on BNB Chain (up 87% QoQ), limit-order rewards for liquidity providers, and Binance’s $250K Altcoin Festival exposure.

These factors tightened supply and boosted trading activity on the BNB Chain, suggesting whales are accumulating before retail momentum builds up.

On-chain signal aggressive buying
In addition to these predictions, on-chain metrics further strengthen CAKE’s bullish outlook.

According to CryptoQuant’s Spot Taker CVD (Cumulative Volume Delta), CAKE witnessed aggressive buying activity over the past week, with not a single red bar, indicating a lack of seller dominance.

Source: CryptoQuant

PancakeSwap (CAKE) strongly bullish derivative
Meanwhile, CoinGlass data recorded a $1.10 million outflow from exchanges in the past 24 hours — a classic signal of accumulation.

Source: CoinGlass

As per data, CAKE’s major liquidation levels stood at $3.273 on the lower side and $3.567 on the upper side. At these levels, traders built $2.09 million worth of long positions and $915.3k worth of short positions.

That alignment between spot outflows and derivative positions supports a short-term bullish bias.

Vivaan Acharya is a Crypto-Economist and Journalist at AMBCrypto who brings a rare depth of financial and economic expertise to the world of digital assets. He holds a Master’s in Economics from the prestigious University of Delhi and has over five years of experience analyzing technology and financial markets.
His foray into the blockchain space began in 2018, marked by his prescient Master's thesis, "Payments and Stablecoin Integration in Banking," which showcased his early understanding of crypto's potential to disrupt traditional finance. Before specializing in crypto, Vivaan honed his skills in rigorous data and technical chart analysis at a major national financial daily, where he covered corporate earnings and market trends.
At AMBCrypto, Vivaan applies this powerful blend of classical economic training and seasoned financial journalism to his work. He is an expert in:
1. Bitcoin and Altcoin Market Analysis
2. Stablecoin Ecosystem Development, and
3 Emerging Crypto Regulations.
Known for his clear, no-nonsense approach, Vivaan translates robust research into straightforward, actionable insights. He is dedicated to demystifying the complexities of blockchain finance, empowering readers to confidently navigate the rapidly evolving digital economy.

Mantle (MNT) has reignited its bullish momentum, surging 30% in the past 24 hours to reclaim the $2.20 level after dipping as low as $1.50 over the weekend. The swift rebound underscores renewed buyer confidence following last week’s sharp correction from record highs.

While MNT remains below its $2.84–$2.86 all-time high, the strong recovery suggests bulls are regaining control, potentially setting the stage for another push toward the upper range if momentum holds.

Spot activity exploded, with daily trading volume up more than 60% to about $1.2 billion, while futures open interest climbed 9% to $269.7 million, a signal that speculative demand is accelerating alongside spot buying.

MNT's price bounces back following major losses on the daily chart. Source: MNTUSD on Tradingview
Fundamental Tailwinds: RWAs, Stablecoin Liquidity, and Exchange Distribution
Beyond the chart, Mantle’s rally is grounded in clear catalysts. The network’s Tokenization-as-a-Service (TaaS)stack is pulling real-world asset issuers on-chain, while the launch of USD1, a new stablecoin building on Mantle, is injecting fresh liquidity and utility into its DeFi rails.

Distribution is another edge: Mantle’s deepening Bybit integration (treasury programs, listings, and roadmap alignment) is funneling sustained order flow, not just one-off hype.

Analysts also highlight Mantle’s modular design (execution on Mantle with EigenDA for data availability and OP-stack upgrades) that lowers costs and improves throughput, important for tokenization, trading, and payments use cases.

Can Mantle (MNT) Bulls Clear $3? The Levels and Scenarios
Momentum favors further upside as a decisive close above $2.87 could open the door to $3.00, with extended targets near $3.60 if volume and open interest continue to rise.

On the downside, $2.50–$2.55 is initial intraday support, followed by the must-hold $1.90–$2.00 zone; losing that would risk a deeper retrace toward $1.60–$1.75 where buyers last reloaded. For now, breadth (spot + derivatives), rising participation, and a tight, orderly trend argue for trend continuation rather than a blow-off top.

Technically, MNT’s clean breakout above $2.00 was followed by strong follow-through and a steady series of higher lows. As long as price holds the $1.90–$2.00 demand zone, the bull structure remains intact, with traders eyeing $2.87 (recent high) and the psychological $3.00 mark next.

Cover image from ChatGPT, MNTUSD chart from Tradingview

Cover image via www.freepik.com

Disclaimer: The opinions expressed by our writers are their own and do not represent the views of U.Today. The financial and market information provided on U.Today is intended for informational purposes only. U.Today is not liable for any financial losses incurred while trading cryptocurrencies. Conduct your own research by contacting financial experts before making any investment decisions. We believe that all content is accurate as of the date of publication, but certain offers mentioned may no longer be available.

XRP has made one of the most spectacular recoveries in recent months, just as traders were preparing for a protracted decline. This move has the potential to completely change the perception of the asset.

After a severe crash last week that destroyed almost 60% of XRP's value in a single day, the token has risen sharply from its lows, regaining important technical levels and surprising market observers who had previously written it off.

Following a flash bottom below $2.00, XRP is currently trading at about $2.55. The strength of this recovery raises the possibility that what at first appeared to be a complete surrender was actually a liquidity flush, a violent shakeout that removed overly leveraged positions and gave the market time to recover.

HOT Stories

XRP/USDT Chart by TradingViewSince it has acted as both a magnet and a barrier for XRP's price action throughout 2025, the 200-day EMA is currently the site of the most significant technical battle. A retest of the $2.90-$3.00 resistance zone, which is the upper trendline of its descending wedge formation, may be possible if XRP is able to break and hold above the 200 EMA and confirm a midterm bullish reversal.

After several compression stages, these structures typically resolve with a breakout, and XRP's sharp volume spike suggests that momentum might be building. However, there is potential for a rally, but the RSI is cautioning of lingering volatility as it recovers from oversold territory while staying below neutral.

In order to verify that this move is real and not just a short-covering bounce, there must be consistent volume and daily closes above $2. As of right now, the market’s sentiment has changed from one of hopelessness to one of curiosity. If this trend keeps up, XRP's recovery may turn out to be one of the most remarkable and surprising in its history.

Bitcoin in controlBitcoin has once again demonstrated its control over the cryptocurrency market by easily breaking through the resistance level of $115,000, which used to serve as a psychological ceiling for traders. This action demonstrates Bitcoin’s capacity to bounce back from turbulence and sustain upward pressure, despite the cautious sentiment of the larger market.

After recovering from its 200-day moving average close to $108,000, Bitcoin has demonstrated incredible strength and is currently trading between $114,300 and $115,500. The current rebound highlights the zone’s significance in Bitcoin’s continuous bull structure, as it has historically been a strong support area during medium-term corrections.

The next major obstacle, however, is located only a few thousand dollars higher at about $116,000, where strong liquidity clusters and short-term sell orders start to accumulate, even though there was a clean break above that level. Experts caution that this area might serve as a reversal zone, causing short-term profit-taking before Bitcoin starts to rise more broadly again.

The market structure is still firmly bullish, though. The RSI is still hovering just below overbought levels, suggesting that there is still space for Bitcoin to grow before exhaustion sets in, while the 50-day EMA is curving upward once more, indicating renewed momentum.

The $120,000-$122,000 range, a historically significant zone that has previously sparked aggressive corrections, would be the next logical target if Bitcoin is able to maintain momentum and absorb liquidity above $116,000. Bitcoin may see a fresh push toward its all-time highs if a confirmed close above that level occurs.

Simply put, Bitcoin’s most recent movement serves as a reminder of its tenacity: whereas most assets find it difficult to gain traction, BTC keeps tearing through resistance levels with ease. The $116,000 liquidity wall could be the beginning of Bitcoin’s next significant breakout, or it could just be a temporary pause.

Shiba Inu zero addition canceledShiba Inu was on the verge of adding another zero to its price following a violent sell-off that rocked the cryptocurrency market as a whole. This would be a symbolic but psychologically damaging threshold for both retail and institutional holders.

However, for the time being, SHIB seems to have escaped the fatal slip despite the extreme pressure and the cascading liquidations across exchanges. Shiba Inu is now trading at about $0.0000109, having recovered significantly from the intraday low that almost fell below the crucial $0.0000100 threshold. That level is a deep support zone created during the accumulation phase of 2023, in addition to being a technical line in the sand.

Buying activity has historically increased in response to SHIB testing this area, resulting in brief relief rallies. The asset quickly recovered lost ground during the crash, even though it briefly fell into adding-zero territory. This was made possible by traders looking for a rebound and short covering.

More significantly, the volume profile indicates that the majority of participants were hesitant to sell below this range, suggesting deep underlying interest and a brief exhaustion of bearish momentum. The asset continues to trade below all significant moving averages, including the 200-day and 100-day EMAs, indicating that macro resistance is still present.

To test its current stabilization, SHIB may retest lower levels if momentum wanes around $0.0000120-$0.0000130. However, SHIB might hold the line as sentiment gradually returns to normal and the overall market exhibits signs of recovery.

Even after one of the market’s most severe flash crashes, the refusal to add another zero shows resiliency and indicates that the community’s speculative energy is still alive and well. In summary, Shiba Inu is not adding a zero just yet, which is a win in this market.

Why the XRP Options Launch Matters
This development could have far-reaching implications for spot ETF approvals and institutional adoption.

The CFTC requires robust surveillance and underlying market capabilities, which are also prerequisites for spot ETFs. Furthermore, strong institutional demand for XRP futures and open interest, addresses the Securities and Exchange Commission’s (SEC) concern about whether there is sufficient market demand and whether XRP would serve a legitimate purpose.

There are several reasons why the CFTC-regulated contracts on XRP launch could fuel speculation about the SEC greenlighting the S-1s for XRP-spot ETFs. These include:

CFTC, a major US regulator, deems XRP safe for institutional derivatives trading.
Genuine institutional demand.
Market evolution beyond spot trading.

Historically, the SEC and the CFTC have not followed the same playbook. The SEC’s main concern was whether XRP qualified as a non-security under the Howey Test.

However, the SEC vs. Ripple case addressed this issue, with Judge Analisa Torres ruling that programmatic sales of XRP did not constitute securities transactions. Crucially, the SEC dropped its appeal against the Programmatic Sales of XRP ruling, paving the way for an XRP-spot ETF market.

For traders questioning the likelihood of an XRP-spot ETF launch, the resolution of the Ripple case and the launch of CFTC-regulated contracts on XRP futures should provide strong assurance.

Marty Party, a prominent crypto commentator with 240,000 followers on X (formerly Twitter), said:

“This marks a major expansion of regulated crypto derivatives beyond Bitcoin (BTC) and Ether (ETH), providing institutions with sophisticated hedging tools amid surging demand for altcoin exposure.”

While conditions appear favorable for an XRP-spot ETF market, the US Government shutdown continues to indirectly delay institutional inflows by slowing SEC processing.

US Senate Takes Center Stage as Shutdown Enters Day 14
On Tuesday, October 14, all eyes will turn to Capitol Hill. The US Senate could hold a vote on a stopgap funding bill as early as today, potentially reopening the US government.

A return to a full SEC office could enable the agency to review and approve the recently amended S-1s, clearing the way for spot ETF issuers to begin trading.

However, reports from Capitol Hill suggest a continued impasse, raising the risk that the shutdown extends into November. Republican Speaker Mike Johnson reportedly stated:

“We’re barreling toward one of the longest shutdowns in American history.”

Johnson has stated that he would not negotiate with the Democrats until they withdraw their health care demands.

Betting platform Kalshi predicts the US government shutdown will last 33 days, down from 37 days, but close to the 35-day shutdown in 2018-2019, the longest in US history. Furthermore, Kalshi puts the odds of the shutdown extending into November at 57%.

The delay of XRP-spot ETF launches beyond their final decision deadlines, ranging from October 18 to November 14, could weigh on XRP prices. However, speculation about an imminent launch could intensify if the Senate passes a stopgap funding bill, potentially sending XRP to $3.

Price Action & Technical Analysis: Will XRP Hold $2.5?
XRP climbed 2.99% on Monday, October 13, following the previous day’s 6.1% rally, closing at $2.6073. The token outperformed the broader market, which gained 0.97%. Despite a three-day winning streak, XRP remained below the 50-day and 200-day Exponential Moving Averages (EMAs), reaffirming a bearish bias.

Key technical levels to watch include:

Support levels: $2.5, $2.0, and $1.9.
Technical resistance levels: the 200-day EMA at $2.6351 and the 50-day EMA at $2.8508.
Resistance levels: $2.7 and $3.0.

Catalysts & Scenarios
In the coming sessions, several key events could dictate near-term price trends:

US-China trade developments.
The US government shutdown.
XRP ETF news (delays or launches) and BlackRock’s stance on an iShares XRP Trust.
Blue-chip companies increase interest in XRP as a treasury reserve asset.
Regulatory milestones: Ripple’s application for a US-chartered bank license, the Market Structure Bill, and SWIFT-related news could also drive near-term price trends.

Bearish Scenario: Risks Below $2.5

BlackRock pours cold water on hopes for an XRP-spot ETF.
US Senate gridlock continues, delaying XRP-spot ETF approvals.
Lawmakers block crypto-friendly regulations, including the Market Structure Bill.
Blue-chip companies show no interest in XRP as a treasury reserve asset.
OCC delays or rejects Ripple’s US-chartered bank license.
SWIFT maintains its market share in the global remittance market, limiting Ripple’s market access.

These bearish scenarios could drag XRP back toward $2.5. A break below $2.5 would expose $2.0.

Bullish Scenario: Path to $3

US and China trade tensions ease.
Senate passage of a stopgap funding bill.
BlackRock files an S-1 for an iShares XRP Trust, and the SEC green-lights XRP-spot ETFs.
Blue-chip companies purchase XRP for treasury purposes, and more payment platforms integrate Ripple technology.
Ripple secures a US-chartered bank license, and the Senate passes the Market Structure Bill.
Ripple makes inroads into the global remittance business at SWIFT’s expense.

These bullish scenarios could drive XRP to $2.7 and bring the key psychological resistance at $3 level.

Renowned crypto analyst Ash Crypto has once again captured the spotlight with his remarkably accurate market forecast. At the start of October, he predicted a sharp correction in Bitcoin and Ethereum prices, forecasting Bitcoin would dip near $106,000 and Ethereum around $3,800 or lower—a prediction that played out exactly as anticipated.

The downturn came after President Trump announced a 100% tariff on Chinese goods, triggering a global market sell-off. Bitcoin plunged to $105,000, while Ethereum briefly fell to $3,500, shaking investor confidence and leading to widespread losses across altcoins.

However, Ash Crypto’s insights don’t end with the crash. He maintains that this correction is merely the calm before a major bull run, predicting that the final quarter of 2025 will be Bitcoin’s strongest ever. According to him, once market sentiment turns excessively bearish, a powerful reversal will ignite a Q4 parabolic rally—sending Bitcoin soaring between $150,000 and $180,000, Ethereum to $8,000–$12,000, and altcoins surging 10x–50x.

Ash Crypto explained that the current pullback is essential for resetting the market before an explosive rebound. “October will likely close with a massive percentage gain,” he stated, suggesting that the rally could begin in the last 10 days of October.

To manage risk, the analyst revealed he remains 85% invested in crypto, keeping 15% in cash to seize buying opportunities during dips. His strategic balance reflects both confidence in his forecast and caution amid market volatility.

If his bullish prediction holds true, investors could soon witness a historic crypto resurgence, marking one of Bitcoin’s most profitable quarters ever.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

XRP has shocked the crypto market with one of its most dramatic comebacks in recent months, defying expectations of a prolonged decline. After plunging nearly 60% in a single day last week, the token has rebounded sharply, regaining key technical levels and reigniting optimism among traders. From a flash low below $2.00, XRP has surged to around $2.55, signaling renewed strength and confidence in the asset’s long-term potential.

Analysts suggest that what initially appeared to be a market capitulation may have been a liquidity flush—an aggressive shakeout that cleared excessive leverage and paved the way for a recovery. The 200-day EMA has emerged as a critical battleground for XRP’s next move. If the token can hold above this level, a retest of the $2.90–$3.00 resistance zone could confirm a medium-term bullish reversal. This range also marks the upper trendline of XRP’s long-standing descending wedge pattern, often a precursor to powerful breakouts.

XRP’s recent volume surge supports the possibility of growing momentum, yet the RSI warns of continued volatility as it recovers from oversold conditions. Sustained daily closes above $2.00 and consistent trading volume are essential to confirm that this rebound is not merely a short-covering rally.

Market sentiment has shifted dramatically—from despair to cautious optimism—as traders begin to question whether this could be the biggest XRP recovery in history. If bullish momentum persists and key resistance levels fall, XRP’s resurgence may mark a defining moment in its 13-year journey, solidifying its position as one of the most resilient assets in the cryptocurrency market.

<Copyright ⓒ TokenPost, unauthorized reproduction and redistribution prohibited>

Dogecoin (DOGE) is showing early signs of stabilization after recent market turbulence, as traders observe renewed buying interest around the $0.21 mark. Following a significant correction from late-September highs, DOGE appears to be forming a base that could set the stage for another upward test.

A growing number of Ukrainian developers and DeFi advocates are publicly challenging Uniswap Labs after discovering that access to the exchange's main web interface is blocked for users in Ukraine.

Ethereum is showing early signs of recovery after a dramatic sell-off on Friday that sent prices plunging to $3,450. The drop came amid what analysts describe as the largest liquidation event in crypto market history, wiping out billions in leveraged positions across major exchanges. While bulls briefly lost control during the panic, ETH has since begun to stabilize, with renewed buying interest emerging near key demand zones.

Onchain analyst Maartunn highlighted that leverage is once again building up on Ethereum, signaling that traders are returning to the market following the reset. According to his data, open interest on ETH surged significantly over the past 24 hours — a sign that speculative activity is resuming as volatility cools. This renewed leverage could set the stage for another decisive move, either fueling a short-term relief rally or inviting further liquidations if momentum fades.

The coming days will be crucial for Ethereum, as bulls attempt to reclaim the $4,000 level to confirm a sustainable recovery. Market sentiment remains cautious but optimistic, with onchain data showing large holders and institutions continuing to accumulate ETH despite recent turbulence — a potential signal of long-term confidence in the asset’s resilience.

Leverage Returns to Ethereum: A Risky Revival In Market Activity
According to Maartunn, Ethereum’s Open Interest has surged by +8.2% within the past 24 hours — a clear sign that leverage is flowing back into the market. This rapid rise comes just days after the largest liquidation event in crypto history, where overleveraged traders were wiped out during the sudden crash. Now, it seems many are trying to “trade their money back,” reigniting short-term volatility and speculation across exchanges.

ETH Price and OI change | Source: Maartunn
Maartunn notes that while these so-called “revenge pumps” often create strong intraday rallies, they rarely sustain long-term momentum. Historically, around 75% of similar leverage-driven recoveries tend to revert, leading to renewed pullbacks once liquidity and funding rates normalize. Only about 25% manage to extend into lasting uptrends, typically when supported by fresh spot buying or renewed institutional inflows.

This data underscores the precarious balance Ethereum currently faces. The jump in Open Interest signals revived market participation, but also introduces the risk of another wave of forced liquidations if traders overextend their positions. For now, ETH’s short-term recovery remains largely fueled by derivatives activity rather than spot demand.

The next few days will be pivotal in determining Ethereum’s direction. If price holds above the $4,000 region with sustained volume, it could confirm that bulls are regaining control. However, a sudden drop in Open Interest or sharp funding spikes could signal that the rally is overextended — setting the stage for another correction.

Ethereum Rebounds, But Resistance Looms Ahead
Ethereum is showing a solid recovery after last week’s dramatic sell-off that drove prices down to the $3,450 level. The daily chart shows that ETH quickly rebounded from the 200-day moving average (red line), confirming it as a major area of demand. Price is now consolidating near $4,150, attempting to build momentum after a strong bullish candle on high volume — a potential sign that buyers are regaining control.

ETH reclaims key levels | Source: ETHUSDT chart on TradingView
However, ETH faces immediate resistance near the $4,250–$4,300 zone, which coincides with the 50-day moving average (blue line). This area previously acted as strong support, and reclaiming it would be essential for confirming a shift back into bullish structure. The 100-day moving average (green line) is now flattening, reflecting the market’s cautious sentiment following the massive liquidation event.

If bulls manage to sustain price action above $4,000, the next targets lie near $4,500 and eventually $4,750. Conversely, failure to hold the 200-day MA could open the door to a deeper retest of $3,600 or lower. For now, Ethereum’s recovery remains technically constructive, but it must overcome these resistance levels to confirm that the recent rebound is more than just a short-term reaction to oversold conditions.

Featured image from ChatGPT, chart from TradingView.com

New legislation seeks to spur innovation, attract foreign investment, and reinforce financial inclusion in Kenya's digital economy.

Key Takeaways

Kenya has officially enacted legislation regulating Bitcoin and other cryptocurrencies.
The Virtual Asset Service Providers Bill assigns regulatory authority over Kenya’s crypto sector to the Central Bank and Capital Markets Authority.

Kenya’s parliament has approved a landmark bill to regulate Bitcoin and other crypto assets, a move that would position the East African nation as a leader in Africa’s fintech landscape.

The Virtual Asset Service Providers Bill designates the Central Bank of Kenya to license issuers of stablecoins and virtual assets, while the Capital Markets Authority will oversee crypto exchanges and trading platforms. The legislation grants formal legal recognition to digital assets.

The move aims to encourage innovation in virtual asset services while attracting international investments in Kenya’s digital economy. The regulatory framework addresses concerns around fraud and market manipulation that have previously hindered crypto adoption in the region.

Kenya’s decision aligns with broader global trends where emerging markets are embracing Bitcoin and crypto to enhance financial inclusion. The legislation establishes clear guidelines for crypto exchanges and service providers operating within the country’s borders.

Disclaimer

Enflux says the $600 million plan reflects a new wave of Asian capital favoring infrastructure tokens that power transaction flow over store-of-value assets.
Oct 14, 2025, 1:48 a.m.

Good Morning, Asia. Here's what's making news in the markets:Welcome to Asia Morning Briefing, a daily summary of top stories during U.S. hours and an overview of market moves and analysis. For a detailed overview of U.S. markets, see CoinDesk's Crypto Daybook Americas.

China Renaissance’s reported plan to raise $600 million for a BNB-focused investment vehicle, with Binance founder Changpeng Zhao's YZi Labs investing alongside, may look like a straightforward bet on Binance’s ecosystem. But Singapore-based market maker Enflux argues it’s something deeper: a signal that Asian institutions are building a different kind of crypto exposure than their Western counterparts.

“Regional capital allocators are seeking exposure to infrastructure tokens that drive transaction flow, not just store-of-value assets,” Enflux said in a note to CoinDesk, framing the China Renaissance move as part of a broader divergence between East and West.

STORY CONTINUES BELOW

BNB is a great example of this. Binance, of course, isn't a listed company, but BNB serves as something very close to a stock. Its value is a proxy for market sentiment and confidence in Binance.

While U.S. and European markets have leaned into tokenized Treasuries, funds, and real-world assets, Asia’s capital markets are increasingly constructing crypto-native liquidity networks centered around exchange, staking, and transaction infrastructure.

"This ties into the broader shift where Asian capital markets are building out their own layer of crypto-native liquidity networks while Western markets tokenized TradFi," Enflux continued.

The logic is straightforward. Value should be accrued by activity, not scarcity. Tron's move to create a publicly listed company to give investors listed exposure to activity on the TRX network – which is heavily used to send USDT around Latin America – follows the same train of thought.

If Enflux’s thesis is right, the China Renaissance fund could be an early blueprint for Asia’s next wave of institutional products: permanent capital vehicles that hold the pipes of the crypto economy, not just its gold.

Market Movement:BTC: BTC is trading above $114,500, relatively flat as the market stabilizes after last weekend's volatility.

ETH: ETH rose 1.5% to $4,230 as network activity picked up, even as U.S.-listed Ethereum ETFs saw $118 million in outflows.

Gold: Gold surged 2% to a record $4,103 an ounce as renewed U.S.-China trade tensions and expectations of further Fed rate cuts drove investors toward safe-haven assets.

Nikkei 225: Asia-Pacific markets traded mixed Tuesday as Trump’s conciliatory remarks on China failed to offset renewed trade tensions, with Japan’s Nikkei 225 down 1.34%.

Elsewhere in Crypto:Crypto market structure bill may need to wait until after the midterm election, says TD Cowen (The Block)Tom Lee's Bitmine Bought the Dip, Adding Over 200K ETH to Ethereum Treasury (CoinDesk)Ripple Is Offering $200K to 'Attack' XRP Ledger Lending Protocol (Decrypt)More For You

Total Crypto Trading Volume Hits Yearly High of $9.72T

Sep 9, 2025

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025

What to know:

Combined spot and derivatives trading on centralized exchanges surged 7.58% to $9.72 trillion in August, marking the highest monthly volume of 2025Gate exchange emerged as major player with 98.9% volume surge to $746 billion, overtaking Bitget to become fourth-largest platformOpen interest across centralized derivatives exchanges rose 4.92% to $187 billionView Full Report

More For You

Bitcoin Miners Lead Crypto Stock Bounce as OpenAI-Broadcom Deal Fuels AI Trade

6 hours ago

Bitfarms, Cipher Mining and Bitdeer posted double-digit gains on Monday as miners keep benefitting from artificial intelligence's surging demand for computing power.

What to know:

Crypto mining stocks led the rebound from Friday's market downturn as Bitfarms, Cipher Mining and Bitdeer posted double-digit gains on Monday. Optimism for the sector was bolstered by OpenAI's deal with Broadcom to build custom chips and Bloom Energy's $5 billion agreement with Brookfield Asset Management to deploy fuel cells for AI data centers.Coinbase, Strategy and Robinhood booked modest gains.Read full story

An analyst has revealed the key Bitcoin charts that could be to keep an eye on while Bitcoin is slowly making recovery from its latest crash.

These Bitcoin Charts Could Be Ones To Watch
In a shock to the market, Bitcoin ended last week with a steep crash, falling from above $122,000 to below $110,000. The coin managed to make some recovery on Sunday, and that rebound has held so far into Monday.

However, while BTC appears to be rebuilding its structure, its direction remains unclear, as noted by CryptoQuant community analyst Maartunn in an X thread. Maartunn has shared a few key charts that could determine whether the recovery will hold or fade.

First, the analyst has revealed a chart that points out a similarity between the recent Bitcoin price action and the November 2021 bull market top.

Looks like the price of the coin recently failed a breakout above the weekly resistance line | Source: @JA_Maartun on X
As displayed in the above graph, BTC broke above its weekly resistance with the recent price rally, but immediately fell below the line after the crash. A similar failed breakout also took place back in November 2021. According to Maartunn, such a trend typically signals exhaustion.

On-chain data also suggests the cryptocurrency is currently trapped below a notable resistance level, as the chart for the UPRD shows.

The data for the latest URPD of BTC | Source: @JA_Maartun on X
The UTXO Realized Price Distribution (URPD) here is an indicator that tells us about the amount of Bitcoin that was last purchased/transferred at the various price levels that the asset has visited in its history.

From the metric’s chart, it’s visible that a significant amount of supply has its cost basis between $117,500 to $120,000. The holders of these coins would naturally be underwater right now, so there is a chance that if BTC recovers to their break-even level, they might panic sell, fearing going into losses again.

Given the scale of the supply involved, selling pressure of this kind could be notable on a retest of the range, potentially making it a major resistance barrier for the asset.

A support level that could be key is the average cost basis or Realized Price of the short-term holders (STHs).

The trend in the Realized Price of the STHs over the last couple of months | Source: @JA_Maartun on X
The line has historically helped the asset find a rebound during bullish trends, with three instances of the trend occurring within the last six weeks alone. The analyst has warned, however, that conviction among the cohort is fading.

The Market Value to Realized Value (MVRV) Ratio suggests profitability among the Bitcoin STHs has been following a long-term decline, with the boundary level of 1 again being retested.

The STH MVRV Ratio has plunged in recent days | Source: @JA_Maartun on X
“If this level breaks, expect downside. If it holds, it confirms demand — but manage risk accordingly!” noted Maartunn in the thread.

BTC Price
At the time of writing, Bitcoin is floating around $114,100, down over 8% in the last seven days.

The coin’s price has made some recovery from its crash | Source: BTCUSDT on TradingView
Featured image from Dall-E, CryptoQuant.com, charts from TradingView.com

Bitcoin price corrected losses and traded above the $114,200 level. BTC is now struggling and might face hurdles near the $116,000 level.

Bitcoin started a recovery wave above the $114,000 resistance level.
The price is trading below $115,000 and the 100 hourly Simple moving average.
There is a bearish trend line forming with resistance at $119,250 on the hourly chart of the BTC/USD pair (data feed from Kraken).
The pair might continue to move down if it trades below the $112,500 zone.

Bitcoin Price Faces Hurdles
Bitcoin price started a recovery wave above the $110,000 pivot level. BTC recovered above the $112,500 and $113,200 resistance levels.

The price climbed above the 50% Fib retracement level of the main drop from the $123,750 swing high to the $100,000 low. The bulls even pushed the price above the $114,000 resistance level. However, there are many hurdles on the upside.

Bitcoin is now trading below $116,000 and the 100 hourly Simple moving average. Besides, there is a bearish trend line forming with resistance at $119,250 on the hourly chart of the BTC/USD pair.

Immediate resistance on the upside is near the $115,000 level. The first key resistance is near the $116,000 level. The next resistance could be $118,150 and the 76.4% Fib retracement level of the main drop from the $123,750 swing high to the $100,000 low.

Source: BTCUSD on TradingView.com
A close above the $118,150 resistance might send the price further higher. In the stated case, the price could rise and test the $119,250 resistance and the trend line. Any more gains might send the price toward the $120,000 level. The next barrier for the bulls could be $122,500.

Another Drop In BTC?
If Bitcoin fails to rise above the $115,000 resistance zone, it could start a fresh decline. Immediate support is near the $113,600 level. The first major support is near the $112,500 level.

The next support is now near the $111,200 zone. Any more losses might send the price toward the $110,500 support in the near term. The main support sits at $110,000, below which BTC might struggle to recover in the short term.

Technical indicators:

Hourly MACD – The MACD is now gaining pace in the bearish zone.

Hourly RSI (Relative Strength Index) – The RSI for BTC/USD is now below the 50 level.

Major Support Levels – $113,500, followed by $112,500.

Major Resistance Levels – $115,000 and $116,000.

Broadcom President and CEO Hock Tan joins 'Mad Money' host Jim Cramer to talk the recently announced deal with OpenAI, competition in the space, and more.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the "Class Period"), of the important November 18, 2025 lead plaintiff deadline.

So what: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

What to do next: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In

Amazon fired a Palestinian engineer who was suspended last month after he protested the company's work with the Israeli government.

Ahmed Shahrour, who worked as a software engineer in Amazon's Whole Foods business in Seattle, received an email on Monday informing him of his termination. When he was suspended in September, Amazon said the decision was the result of messages Shahrour posted on Slack criticizing the company's ties to Israel.

Amazon said its investigation found Shahrour had violated the company's standards of conduct, written communication policy and acceptable use policy, alleging that he "misused company resources, including by posting numerous non-work-related messages pertaining to the Israel-Palestine conflict."

"In the next 24hrs you will receive an email with detailed information about your termination, including information about your benefits and final pay," an Amazon human resources employee wrote in a message to Shahrour that was obtained by CNBC. "We appreciate the contributions you've made during your time with Amazon and wish you the best in your future endeavors."

An employee group associated with Shahrour put out an afternoon press release saying that he was fired after a five-week suspension "for protesting Amazon's $1.2 billion contract with the Israeli government and military, known as Project Nimbus, which he states constitutes collaboration in the ongoing genocide in Gaza."

Shahrour had urged the company to drop the contract that involves Amazon providing the Israeli government with artificial intelligence tools, data centers and other infrastructure. He also protested and handed out flyers at Amazon's downtown Seattle headquarters.

In a statement to CNBC, Shahrour said his firing is "a blatant act of retaliation designed to silence dissent from Palestinian voices within Amazon and shield Amazon's collaboration in the genocide from internal scrutiny."

watch now

Amazon spokesperson Brad Glasser told CNBC in a statement that the company doesn't tolerate "discrimination, harassment or threatening behavior or language of any kind in our workplace."

"When any conduct of that nature is reported, we investigate it and take appropriate action based on our findings," Glasser said.

Shahrour's termination comes on the same day that Palestinian militant group Hamas released the first seven surviving Israeli hostages, marking the first stage of a ceasefire deal brokered with the help of U.S. President Donald Trump. As part of the agreement, Israel was also scheduled to free nearly 2,000 Palestinian detainees and prisoners later in the day.

The war started just over two years ago, when Hamas-led militants attacked southern Israel on Oct. 7, 2023, killing roughly 1,200 people and taking hundreds of hostages. Israel followed with a sustained assault that killed more than 67,000 Palestinians, including thousands of civilians, according to Gaza's Health Ministry.

Across the tech industry, workers have become more outspoken in their criticism of business dealings with the Israeli military.

On Thursday, a Microsoft engineer resigned after 13 years at the software giant, claiming the company continues to sell cloud services to the Israeli military and that executives won't discuss the war in Gaza. Scott Sutfin-Glowski, a principal software engineer, informed colleagues in a letter that, "I can no longer accept enabling what may be the worst atrocities of our time."

In the letter, he referred to a February Associated Press article that said Israel's military had at least 635 Microsoft subscriptions, and he claimed the vast majority of them remain active.

Microsoft fired two employees in August who participated in a protest inside the company's headquarters. In April 2024, Google terminated 28 employees after a series of protests against labor conditions and its involvement in Project Nimbus.

Amazon hasn't acknowledged the Nimbus contract beyond stating that it provides technology to customers "wherever they are located." Google has previously said it provides generally available cloud computing services to the Israeli government that aren't "directed at highly sensitive, classified or military workloads." Microsoft said in August that most of its work with Israel Defense Forces involves cybersecurity for the country, and that the company intends to provide technology in an ethical way.

— CNBC's Jordan Novet contributed to this report.

watch now

ADELAIDE, AU / ACCESS Newswire / October 13, 2025 / Barton Gold Holdings Limited (ASX:BGD)(FRA:BGD3)(OTCQB:BGDFF) (Barton or Company) advises that the attached presentation has been presented today at the Australian Gold Conference. A copy of this presentation can be accessed on the ASX website, the investor section of Barton's website, or directly by clicking here.

VALHALLA, N.Y.--(BUSINESS WIRE)--FUJIFILM North America Corporation, Imaging Division, today announced the addition of instax AiR Studio™ and Click to Collage features to its instax mini Link™ for Nintendo Switch App1. The free, downloadable app will be compatible with all instax mini Link™ smartphone printers as well as Nintendo Switch and Nintendo Switch 2. With the App, users can share their favorite character moments with fellow gamers by printing a custom, one-of-a-kind instax™ mini photo2.

WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease (“IBD”) and other immune-mediated diseases, today announced the pricing of its previously announced underwritten public offering of 14,864,865 shares of its common stock at a price to the public of $18.50 per share. The gross proceeds to the Company from this offering are expected to be approximately $275.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters of the offering an option for a period of 30 days to purchase up to an additional 2,229,729 shares of the Company's common stock at the public offering price, less the underwriting discount.

The offering is expected to close on or about October 15, 2025, subject to satisfaction of customary closing conditions. Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated are acting as the joint book-running managers for the offering. Wedbush Securities Inc. is acting as lead manager for the offering.

A registration statement on Form S-3 (File No. 333-285341) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on March 7, 2025. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A preliminary prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be  filed with the SEC and is available on the SEC’s website located at http://www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus related to the offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388 or by email at [email protected]; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at [email protected];  Leerink Partners LLC, Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at [email protected] or Stifel, Nicolaus & Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, California 94104, telephone: (415) 364‐2720 or by emailing [email protected] final terms of the offering will be disclosed in a final prospectus supplement to be filed with the SEC.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Spyre Therapeutics

Spyre Therapeutics is a clinical-stage biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) and other immune-mediated disease products by combining best-in-class antibody engineering, dose optimization, and rational therapeutic combinations. Spyre’s pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.

Safe Harbor / Forward Looking Statements

This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical fact are forward-looking statements. These forward-looking statements include statements regarding Spyre’s expectations regarding the consummation of the offering and the satisfaction of customary closing conditions with respect to the offering. The words “believe,” “may,” “will,” “potentially,” “estimate,” “continue,” “anticipate,” “predict,” “target,” “intend,” “could,” “would,” “should,” “project,” “plan,” “expect,” the negatives of these terms, and similar expressions that convey uncertainty of future events or outcomes are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions related to the offering, uncertainties and risks arising from regulatory feedback, including potential disagreement by regulatory authorities with the Company’s clinical trial design, interpretation of data and the Company’s ongoing or planned clinical trials for the Company’s product candidates, including the Company’s planned SKYWAY-RD Phase 2 clinical trial design and the Company’s plans for and timing of cohort initiation for combination arms for the ongoing SKYLINE-UC Phase 2 platform trial across different jurisdictions; the potential for final clinical data not being consistent with or different than the previously disclosed data for the Company’s programs; the expected or potential impact of macroeconomic conditions, including inflationary pressures, rising interest rates, general economic slowdown or a recession, changes in tariff/trade and monetary policy, volatile market conditions, financial institution instability, as well as geopolitical instability, including the ongoing military conflicts between Ukraine and Russia, conflicts in the Middle East, and geopolitical tensions between the United States and other countries, including China, on the Company’s operations; the implementation of changes in law, tariffs, sanctions, export or import controls, and other government measures that could impact the Company’s business operations, including restricting international trade by the United States, China or other countries and the BIOSECURE Act or similar act if passed into law; and those risks described in the Company’s most recent Annual Report on Form 10-K, its subsequent Quarterly Reports on Form 10-Q, as well as in other filings and reports that the Company makes from time to time with the SEC. Moreover, the Company operates in a very competitive and rapidly changing environment, and new risks emerge from time to time. It is not possible for the Company’s management to predict all risks, nor can the Company assess the impact of all factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements it may make. In light of these risks, uncertainties, and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. The Company undertakes no obligation to update publicly any forward-looking statement for any reason after the date of this press release to conform these statements to actual results, to reflect changes in the Company's expectations, or otherwise, except as required by law.

For Investors: 
Eric McIntyre
VP of Finance and Investor Relations
Spyre Therapeutics
[email protected] 

For Media: 
Josie Butler, 1AB
[email protected] 

TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that LEQEMBI® IQLIK™, a subcutaneous autoinjector formulation of lecanemab (generic name), for the treatment of Alzheimer’s disease (AD) has been selected by TIME as one of the “Best Inventions of 2025” in the Medical and Healthcare category.

TIME’s annual list of the Best Inventions features 300 extraordinary innovations changing lives. To compile the 2025 list, TIME solicited nominations from TIME editors and correspondents around the world, and through an online application process, paying special attention to growing fields such as health care and AI. TIME then evaluated each contender on a number of key factors, including originality, efficacy, ambition, and impact. For more information, please visit
time.com/collections/best-inventions-2025/.

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and their care partners continue to slow disease progression following the 18-month initial treatment period. The treatment was approved in the U.S. in August 2025 and launched on October 6. LEQEMBI IQLIK offers patients and their care partners the potential to shorten administration time (approximate injection time of 15 seconds), providing an option to continue treatment without having to worry about visiting an infusion center. Moreover, it has the potential to reduce healthcare resources associated with intravenous (IV) maintenance dosing, such as preparation for infusion and nurse monitoring, while increasing infusion capacity for new eligible patients to begin initiation treatment and streamlining the overall AD treatment pathway.

LEQEMBI, recognized as one of TIME’s “Best Inventions of 2023,” is the first approved anti-amyloid treatment for AD shown to slow disease progression and cognitive and functional decline in adults with Mild Cognitive Impairment (MCI) or mild dementia stage of disease (collectively referred to as early AD). LEQEMBI has been approved in 50 countries and is under regulatory review in 10 countries. In early September, Eisai initiated a rolling Supplemental Biologics License Application (sBLA) to the U.S. FDA for LEQEMBI IQLIK as a subcutaneous starting dose for the treatment of early AD under Fast Track Status.

Eisai serves as the lead of LEQEMBI development and regulatory submissions globally with Eisai and Biogen co-commercializing and co-promoting the product and Eisai having final decision-making authority.

INDICATION

LEQEMBI® is indicated for the treatment of Alzheimer’s disease (AD). Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment (MCI) or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

IMPORTANT SAFETY INFORMATION

WARNING: AMYLOID-RELATED IMAGING ABNORMALITIES (ARIA) Monoclonal antibodies directed against aggregated forms of beta amyloid, including LEQEMBI, can cause ARIA, characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events, including seizure and status epilepticus, can occur. ARIA can be fatal. Serious intracerebral hemorrhages (ICH) >1 cm, some of which have been fatal, have been observed with this class of medications. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy to a patient being treated with LEQEMBI. Apolipoprotein E ε4 (ApoE ε4) Homozygotes: Patients who are ApoE ε4 homozygotes (~15% of patients with AD) treated with this class of medications have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with LEQEMBI; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA. Consider the benefit of LEQEMBI for the treatment of AD and the potential risk of serious ARIA events when deciding to initiate treatment with LEQEMBI. CONTRAINDICATION

Contraindicated in patients with serious hypersensitivity to lecanemab-irmb or to any of the excipients. Reactions have included angioedema and anaphylaxis.

WARNINGS AND PRECAUTIONS

AMYLOID-RELATED IMAGING ABNORMALITIES

Medications in this class, including LEQEMBI, can cause ARIA-E, which can be observed on MRI as brain edema or sulcal effusions, and ARIA-H, which includes microhemorrhage and superficial siderosis. ARIA can occur spontaneously in patients with AD, particularly in patients with MRI findings suggestive of cerebral amyloid angiopathy (CAA), such as pretreatment microhemorrhage or superficial siderosis. ARIA-H generally occurs with ARIA-E. Reported ARIA symptoms may include headache, confusion, visual changes, dizziness, nausea, and gait difficulty. Focal neurologic deficits may also occur. Symptoms usually resolve over time.

Incidence of ARIA
Symptomatic ARIA occurred in 3% and serious ARIA symptoms in 0.7% with LEQEMBI. Clinical ARIA symptoms resolved in 79% of patients during the period of observation. ARIA, including asymptomatic radiographic events, was observed: LEQEMBI, 21%; placebo, 9%. ARIA-E was observed: LEQEMBI, 13%; placebo, 2%. ARIA-H was observed: LEQEMBI, 17%; placebo, 9%. No increase in isolated ARIA-H was observed for LEQEMBI vs placebo.

Incidence of ICH
ICH >1 cm in diameter was reported in 0.7% with LEQEMBI vs 0.1% with placebo. Fatal events of ICH in patients taking LEQEMBI have been observed.

Risk Factors of ARIA and ICH
ApoE ε4 Carrier Status
Of the patients taking LEQEMBI, 16% were ApoE ε4 homozygotes, 53% were heterozygotes, and 31% were noncarriers. With LEQEMBI, ARIA was higher in ApoE ε4 homozygotes (LEQEMBI: 45%; placebo: 22%) than in heterozygotes (LEQEMBI: 19%; placebo: 9%) and noncarriers (LEQEMBI: 13%; placebo: 4%). Symptomatic ARIA-E occurred in 9% of ApoE ε4 homozygotes vs 2% of heterozygotes and 1% of noncarriers. Serious ARIA events occurred in 3% of ApoE ε4 homozygotes and in ~1% of heterozygotes and noncarriers. The recommendations on management of ARIA do not differ between ApoE ε4 carriers and noncarriers.

Radiographic Findings of CAA
Neuroimaging findings that may indicate CAA include evidence of prior ICH, cerebral microhemorrhage, and cortical superficial siderosis. CAA has an increased risk for ICH. The presence of an ApoE ε4 allele is also associated with CAA.

The baseline presence of at least 2 microhemorrhages or the presence of at least 1 area of superficial siderosis on MRI, which may be suggestive of CAA, have been identified as risk factors for ARIA. Patients were excluded from Clarity AD for the presence of >4 microhemorrhages and additional findings suggestive of CAA (prior cerebral hemorrhage >1 cm in greatest diameter, superficial siderosis, vasogenic edema) or other lesions (aneurysm, vascular malformation) that could potentially increase the risk of ICH.

Concomitant Antithrombotic or Thrombolytic Medication
In Clarity AD, baseline use of antithrombotic medication (aspirin, other antiplatelets, or anticoagulants) was allowed if the patient was on a stable dose. Most exposures were to aspirin. Antithrombotic medications did not increase the risk of ARIA with LEQEMBI. The incidence of ICH: 0.9% in patients taking LEQEMBI with a concomitant antithrombotic medication vs 0.6% with no antithrombotic and 2.5% in patients taking LEQEMBI with an anticoagulant alone or with antiplatelet medication such as aspirin vs none in patients receiving placebo.

Fatal cerebral hemorrhage has occurred in 1 patient taking an anti-amyloid monoclonal antibody in the setting of focal neurologic symptoms of ARIA and the use of a thrombolytic agent.

Additional caution should be exercised when considering the administration of antithrombotics or a thrombolytic agent (e.g., tissue plasminogen activator) to a patient already being treated with LEQEMBI. Because ARIA-E can cause focal neurologic deficits that can mimic an ischemic stroke, treating clinicians should consider whether such symptoms could be due to ARIA-E before giving thrombolytic therapy in a patient being treated with LEQEMBI.

Caution should be exercised when considering the use of LEQEMBI in patients with factors that indicate an increased risk for ICH and, in particular, patients who need to be on anticoagulant therapy or patients with findings on MRI that are suggestive of CAA.

Radiographic Severity With LEQEMBI
Most ARIA-E radiographic events occurred within the first 7 doses, although ARIA can occur at any time, and patients can have >1 episode. Maximum radiographic severity of ARIA-E with LEQEMBI was mild in 4%, moderate in 7%, and severe in 1% of patients. Resolution on MRI occurred in 52% of ARIA-E patients by 12 weeks, 81% by 17 weeks, and 100% overall after detection. Maximum radiographic severity of ARIA-H microhemorrhage with LEQEMBI was mild in 9%, moderate in 2%, and severe in 3% of patients; superficial siderosis was mild in 4%, moderate in 1%, and severe in 0.4% of patients. With LEQEMBI, the rate of severe radiographic ARIA-E was highest in ApoE ε4 homozygotes (5%) vs heterozygotes (0.4%) or noncarriers (0%). With LEQEMBI, the rate of severe radiographic ARIA-H was highest in ApoE ε4 homozygotes (13.5%) vs heterozygotes (2.1%) or noncarriers (1.1%).

Monitoring and Dose Management Guidelines
Baseline brain MRI and periodic monitoring with MRI are recommended. Enhanced clinical vigilance for ARIA is recommended during the first 14 weeks of treatment. Depending on ARIA-E and ARIA-H clinical symptoms and radiographic severity, use clinical judgment when considering whether to continue dosing or to temporarily or permanently discontinue LEQEMBI. If a patient experiences ARIA symptoms, clinical evaluation should be performed, including MRI if indicated. If ARIA is observed on MRI, careful clinical evaluation should be performed prior to continuing treatment.

HYPERSENSITIVITY REACTIONS

Hypersensitivity reactions, including angioedema, bronchospasm, and anaphylaxis, have occurred with LEQEMBI. Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.

INFUSION-RELATED REACTIONS (IRRs)

IRRs were observed—LEQEMBI: 26%; placebo: 7%—and most cases with LEQEMBI (75%) occurred with the first infusion. IRRs were mostly mild (69%) or moderate (28%). Symptoms included fever and flu-like symptoms (chills, generalized aches, feeling shaky, and joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation.

IRRs can occur during or after the completion of infusion. In the event of an IRR during the infusion, the infusion rate may be reduced or discontinued, and appropriate therapy initiated as clinically indicated. Consider prophylactic treatment prior to future infusions with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids.

ADVERSE REACTIONS

The most common adverse reactions reported in ≥5% with LEQEMBI infusion every 2 weeks and ≥2% higher than placebo were IRRs (LEQEMBI: 26%; placebo: 7%), ARIA-H (LEQEMBI: 14%; placebo: 8%), ARIA-E (LEQEMBI: 13%; placebo: 2%), headache (LEQEMBI: 11%; placebo: 8%), superficial siderosis of central nervous system (LEQEMBI: 6%; placebo: 3%), rash (LEQEMBI: 6%; placebo: 4%), and nausea/vomiting (LEQEMBI: 6%; placebo: 4%)Safety profile of LEQEMBI IQLIK for maintenance treatment was similar to LEQEMBI infusion. Patients who received LEQEMBI IQLIK experienced localized and systemic (less frequent) injection-related reactions (mild to moderate in severity) LEQEMBI (lecanemab-irmb) is available:

Intravenous infusion: 100 mg/mLSubcutaneous injection: 200 mg/mL Please see full Prescribing Information for LEQEMBI, including Boxed WARNING.

MEDIA CONTACTS Eisai Co., Ltd.
Public Relations Department
TEL: +81 (0)3-3817-5120Eisai Europe, Ltd.
EMEA Communications Department
+44 (0) 797 487 9419

[email protected] Inc. (U.S.)
Libby Holman
+1-201-753-1945

[email protected] Inc.
Madeleine Shin
+1-781-464-3260
[email protected] INVESTOR CONTACTS Eisai Co., Ltd.
Investor Relations Department
TEL: +81 (0) 3-3817-5122Biogen Inc.
Tim Power
+ 1-781-464-2442
[email protected] Notes to Editors

1.   About lecanemab (generic name, brand name: LEQEMBI®)

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and insoluble forms of amyloid-beta (Aβ).

Lecanemab has been approved in 50 countries and is under regulatory review in 10 countries. The supplemental Biologics License Application (sBLA) for intravenous (IV) maintenance dosing of the treatment was approved in the U.S.in January 2025 and China in September 2025, and applications have been filed in 5 countries and regions.

LEQEMBI's approvals in these countries was based on Phase 3 data from Eisai's, global Clarity AD clinical trial, in which it met its primary endpoint and all key secondary endpoints with statistically significant results. The primary endpoint was the global cognitive and functional scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). In the Clarity AD clinical trial, treatment with lecanemab reduced clinical decline on CDR-SB by 27% at 18 months compared to placebo. The mean CDR-SB score at baseline was approximately 3.2 in both groups. The adjusted least-squares mean change from baseline at 18 months was 1.21 with lecanemab and 1.66 with placebo (difference, −0.45; 95% confidence interval [CI], −0.67 to −0.23; P<0.001). In addition, the secondary endpoint from the AD Cooperative Study-Activities of Daily Living Scale for Mild Cognitive Impairment (ADCS-MCI-ADL), which measures information provided by people caring for patients with AD, noted a statistically significant benefit of 37% compared to placebo. The adjusted mean change from baseline at 18 months in the ADCS-MCI-ADL score was −3.5 in the lecanemab group and −5.5 in the placebo group (difference, 2.0; 95% CI, 1.2 to 2.8; P<0.001). The ADCS MCI-ADL assesses the ability of patients to function independently, including being able to dress, feed themselves and participate in community activities. The most common adverse events (>10%) in the lecanemab group were infusion reactions, ARIA-H (combined cerebral microhemorrhages, cerebral macrohemorrhages, and superficial siderosis), ARIA-E (edema/effusion), headache, and fall.

The subcutaneous maintenance dosing approval is based on LEQEMBI subcutaneous (SC) sub-studies of the Phase 3 Clarity AD open-label extension (OLE) trial in individuals with early AD which evaluated a range of subcutaneous doses. Data shows that transitioning to the weekly LEQEMBI IQLIKTM autoinjector after 18 months of the initiation dose (10 mg/kg IV every two weeks) maintains clinical and biomarker benefits comparable to continued IV dosing. The safety of LEQEMBI IQLIK autoinjector was studied in over 600 patients at a range of doses as part of the Clarity AD OLE. Across all subcutaneous doses, the safety profile was similar to that of the IV maintenance treatment with one key difference: systemic reactions were much less common with subcutaneous dosing—less than 1% compared to approximately 26% with IV infusions. ARIA rates in patients who received a weekly 360 mg subcutaneous maintenance dose were similar to ARIA rates reported in patients who continued with the IV dose after 18 months and are similar to the background rates of ARIA in patients without treatment.

Since July 2020, the Phase 3 clinical study (AHEAD 3-45) for individuals with preclinical AD, meaning they are clinically normal and have intermediate or elevated levels of amyloid in their brains, is ongoing. AHEAD 3-45 is conducted as a public-private partnership between the Alzheimer's Clinical Trial Consortium that provides the infrastructure for academic clinical trials in AD and related dementias in the U.S, funded by the National Institute on Aging, part of the National Institutes of Health, Eisai, and Biogen. Since January 2022, the Tau NexGen clinical study for Dominantly Inherited AD (DIAD), that is conducted by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is ongoing and includes lecanemab as the backbone anti-amyloid therapy.

2.   About the Collaboration between Eisai and Biogen for AD

Eisai and Biogen have been collaborating on the joint development and commercialization of AD treatments since 2014. Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product and Eisai having final decision-making authority.

3.   About the Collaboration between Eisai and BioArctic for AD

Since 2005, Eisai and BioArctic have had a long-term collaboration regarding the development and commercialization of AD treatments. Eisai obtained the global rights to study, develop, manufacture and market lecanemab for the treatment of AD pursuant to an agreement with BioArctic in December 2007. The development and commercialization agreement on the antibody lecanemab back-up was signed in May 2015.

4.   About Eisai Co., Ltd.

Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.

In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.

For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. For audiences based in the UK and Europe, please visit www.eisai.eu and Eisai EMEA LinkedIn.

5.   About Biogen

Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patient’s lives and to create value for shareholders and our communities. We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes. Our approach is to take bold risks, balanced with return on investment to deliver long-term growth.

The company routinely posts information that may be important to investors on its website at www.biogen.com. Follow Biogen on social media – Facebook, LinkedIn, X, YouTube.

Biogen Safe Harbor
This news release contains forward-looking statements, including about the potential clinical effects of lecanemab; the potential benefits, safety and efficacy of lecanemab; potential regulatory discussions, submissions and approvals and the timing thereof including for lecanemab-irmb (LEQEMBI IQLIK); the potential to streamline the Alzheimer's disease treatment pathway; the anticipated benefits and potential of Biogen's collaboration arrangements with Eisai; the potential of Biogen's commercial business and pipeline programs, including lecanemab; and risks and uncertainties associated with drug development and commercialization. These forward-looking statements may be accompanied by such words as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “hope,” “intend,” “may,” “objective,” “plan,” “possible,” “potential,” “predict,” “project,” “prospect,” “should,” “target,” “will,” “would,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. You should not place undue reliance on these statements. Given their forward-looking nature, these statements involve substantial risks and uncertainties that may be based on inaccurate assumptions and could cause actual results to differ materially from those reflected in such statements. These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, uncertainty of long-term success in developing, licensing, or acquiring other product candidates or additional indications for existing products; expectations, plans and prospects relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products; our ability to effectively implement our corporate strategy; the successful execution of our strategic and growth initiatives, including acquisitions; the risk that positive results in a clinical trial may not be replicated in subsequent or confirmatory trials or success in early stage clinical trials may not be predictive of results in later stage or large scale clinical trials or trials in other potential indications; risks associated with clinical trials, including our ability to adequately manage clinical activities, unexpected concerns that may arise from additional data or analysis obtained during clinical trials, regulatory authorities may require additional information or further studies, or may fail to approve or may delay approval of our drug candidates; the occurrence of adverse safety events, restrictions on use with our products, or product liability claims; and any other risks and uncertainties that are described in other reports we have filed with the U.S. Securities and Exchange Commission.

These statements speak only as of the date of this press release and are based on information and estimates available to us at this time. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors are cautioned not to put undue reliance on forward-looking statements. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and in our subsequent reports on Form 10-Q and Form 10-K, in each case including in the sections thereof captioned “Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in our subsequent reports on Form 8-K. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements whether as a result of any new information, future events, changed circumstances or otherwise.

News Summary:

NVIDIA founder and CEO Jensen Huang delivers DGX Spark to Elon Musk at SpaceX.This week, NVIDIA and its partners are shipping DGX Spark, the world’s smallest AI supercomputer, delivering NVIDIA’s AI stack in a compact desktop form factor.Acer, ASUS, Dell Technologies, GIGABYTE, HPI, Lenovo and MSI debut DGX Spark systems, expanding access to powerful AI computing.Built on the NVIDIA Grace Blackwell architecture, DGX Spark integrates NVIDIA GPUs, CPUs, networking, CUDA libraries and NVIDIA AI software, accelerating agentic and physical AI development. SANTA CLARA, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- NVIDIA today announced it will start shipping NVIDIA DGX Spark™, the world’s smallest AI supercomputer.

AI workloads are quickly outgrowing the memory and software capabilities of the PCs, workstations and laptops millions of developers rely on today — forcing teams to shift work to the cloud or local data centers.

As a new class of computer, DGX Spark delivers a petaflop of AI performance and 128GB of unified memory in a compact desktop form factor, giving developers the power to run inference on AI models with up to 200 billion parameters and fine-tune models of up to 70 billion parameters locally. In addition, DGX Spark lets developers create AI agents and run advanced software stacks locally.

“In 2016, we built DGX-1 to give AI researchers their own supercomputer. I hand-delivered the first system to Elon at a small startup called OpenAI — and from it came ChatGPT, kickstarting the AI revolution,” said Jensen Huang, founder and CEO of NVIDIA. “DGX-1 launched the era of AI supercomputers and unlocked the scaling laws that drive modern AI. With DGX Spark, we return to that mission — placing an AI computer in the hands of every developer to ignite the next wave of breakthroughs.”

DGX Spark brings together the full NVIDIA AI platform — including GPUs, CPUs, networking, CUDA® libraries and the NVIDIA AI software stack — into a system small enough for a lab or an office, yet powerful enough to accelerate agentic and physical AI development. By combining breakthrough performance with the reach of the NVIDIA ecosystem, DGX Spark transforms the desktop into an AI development platform.

DGX Spark systems deliver up to 1 petaflop of AI performance, accelerated by a NVIDIA GB10 Grace Blackwell Superchip, NVIDIA ConnectX®-7 200 Gb/s networking and NVIDIA NVLink™-C2C technology, providing 5x the bandwidth of fifth-generation PCIe with 128GB of CPU-GPU coherent memory.

The NVIDIA AI software stack is preinstalled to enable developers to start working on AI projects out of the box. With DGX Spark, developers can access NVIDIA AI ecosystem tools including models, libraries, and NVIDIA NIM™ microservices, enabling local workflows such as customizing Black Forest Labs’ FLUX.1 models to refine image generation, creating a vision search and summarization agent using the NVIDIA Cosmos™ Reason vision language model, or building an AI chatbot using Qwen3 that is optimized for DGX Spark.

To celebrate DGX Spark shipping worldwide, Huang hand-delivered one of the first units of DGX Spark to Elon Musk, chief engineer at SpaceX, today in Starbase, Texas. The exchange was a connection to the supercomputer’s origins, as Musk was among the team that received the first NVIDIA DGX™-1 supercomputer from Huang in 2016.

Other early recipients of DGX Spark, including Anaconda, Cadence, ComfyUI, Docker, Google, Hugging Face, JetBrains, LM Studio, Meta, Microsoft, Ollama and Roboflow, are testing, validating and optimizing their tools, software and models for DGX Spark.

Research organizations around the world, including the NYU Global Frontier Lab, previewed DGX Spark to boost their AI development.

“DGX Spark allows us to access peta-scale computing on our desktop,” said Kyunghyun Cho, professor of computer and data science at the NYU Global Frontier Lab. “This new way to conduct AI research and development enables us to rapidly prototype and experiment with advanced AI algorithms and models — even for privacy- and security-sensitive applications, such as healthcare.”

NVIDIA DGX Spark Now Shipping
Starting Wednesday, Oct. 15, DGX Spark can be ordered on NVIDIA.com. Partner systems will be available from Acer, ASUS, Dell Technologies, GIGABYTE, HP, Lenovo, MSI as well as Micro Center stores in the U.S., and from NVIDIA channel partners worldwide.

About NVIDIA
NVIDIA (NASDAQ: NVDA) is the world leader in AI and accelerated computing.

For further information, contact:
Alex Shapiro
Public Relations
NVIDIA Corporation
+1-415-608-5044
[email protected] 

Certain statements in this press release including, but not limited to, statements as to: with DGX Spark, NVIDIA placing an AI computer in the hands of every developer to ignite the next wave of breakthroughs; the benefits, impact, performance, and availability of NVIDIA’s products, services, and technologies; expectations with respect to NVIDIA’s third party arrangements, including with its collaborators and partners; expectations with respect to technology developments; and other statements that are not historical facts are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the “safe harbor” created by those sections based on management’s beliefs and assumptions and on information currently available to management and are subject to risks and uncertainties that could cause results to be materially different than expectations. Important factors that could cause actual results to differ materially include: global economic and political conditions; NVIDIA’s reliance on third parties to manufacture, assemble, package and test NVIDIA’s products; the impact of technological development and competition; development of new products and technologies or enhancements to NVIDIA’s existing product and technologies; market acceptance of NVIDIA’s products or NVIDIA’s partners’ products; design, manufacturing or software defects; changes in consumer preferences or demands; changes in industry standards and interfaces; unexpected loss of performance of NVIDIA’s products or technologies when integrated into systems; and changes in applicable laws and regulations, as well as other factors detailed from time to time in the most recent reports NVIDIA files with the Securities and Exchange Commission, or SEC, including, but not limited to, its annual report on Form 10-K and quarterly reports on Form 10-Q. Copies of reports filed with the SEC are posted on the company’s website and are available from NVIDIA without charge. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, NVIDIA disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.

© 2025 NVIDIA Corporation. All rights reserved. NVIDIA, the NVIDIA logo, ConnectX, CUDA, DGX, NVIDIA Cosmos, NVIDIA NIM and NVLink are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries. Other NVIDIA trademarks and service marks not listed herein are also the property of NVIDIA Corporation. All rights reserved. All other company and product names are trademarks or registered trademarks of their respective owners. Features, pricing, availability and specifications are subject to change without notice.

Photos accompanying this announcement are available at 

https://www.globenewswire.com/NewsRoom/AttachmentNg/ee138c12-fd60-431a-9b43-c6fb1a34287c

https://www.globenewswire.com/NewsRoom/AttachmentNg/a6e9e492-6a02-47d9-9042-856c567fd7c9

NVIDIA DGX Spark
As a new class of computer, DGX Spark delivers a petaflop of AI performance and 128GB of unified mem...

Asia-Pacific markets were set to open lower Tuesday, breaking ranks with gains on Wall Street after U.S. President Donald Trump softened his stance on China.

Following a slew of tit-for-tat trade restrictions and heated exchanges, Trump said "Don't worry about China, it will all be fine!" in a Truth Social post Monday.

China has slapped fees on U.S. ships for docking at its ports, in retaliation for similar charges imposed by Washington on Chinese ships. Both fees are scheduled to kick in today.

Japan's benchmark Nikkei 225 index was set for a lower open, with its futures contract in Chicago trading at 47,235, and its counterpart in Osaka at 46,980, against the index's Monday close of 48,088.8.

Australia's ASX/S&P 200 was down 0.25%.

Hong Kong's Hang Seng Index was set to open lower, with its futures contract trading at 25,794, against the index's previous close of 25,889.48.

U.S. equity futures were little changed in early Asian hours. On Monday stateside, the key benchmarks recovered a significant chunk of their losses suffered last week after Trump's Truth Social post.

Overnight, the Dow Jones Industrial Average closed higher by 587.98 points, or 1.29%, to 46,067.58, which equates to 67% of its Friday loss. The S&P 500 rose 1.56% to finish at 6,654.72, retracing 56% of its prior decline. The Nasdaq Composite popped 2.21% to settle at 22,694.61 as beaten-down technology stocks led the bounce.

— CNBC's Alex Harring, Sarah Min and Fred Imbert contributed to this report.

A fire knocked a crucial aluminum supplier offline until next year. Moneymaking F-150 trucks are vulnerable.

, /PRNewswire/ -- 

Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Soleno Therapeutics, Inc. (NASDAQ: SLNO) resulting from allegations that Soleno Therapeutics may have issued materially misleading business information to the investing public.

So What: If you purchased Soleno Therapeutics securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses.

What to do next: To join the prospective class action, go to https://rosenlegal.com/submit-form/?case_id=43959 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.

What is this about: On August 15, 2025, Investing.com published a story entitled "Soleno Therapeutics stock falls after Scorpion Capital short report." The article stated that Soleno Therapeutics stock had fallen "following a short report from Scorpion Capital that raised serious concerns about the company's recently approved Prader-Willi syndrome treatment, VYKAT XR." It further stated that the Scorpion Capital report "highlighted personal safety issues," and that it "suggested the drug may be at risk of being withdrawn from the market or facing a significant decline in new prescriptions."

On this news, Soleno Therapeutics' stock fell 7.4% on August 15, 2025. It fell a further 4.9% on the next trading day.

Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
www.rosenlegal.com

SOURCE THE ROSEN LAW FIRM, P. A.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+

Newsrooms &

Influencers

9k+

Digital Media

Outlets

270k+

Journalists

Opted In